Ken Frazier, Merck CEO (Bess Adler/Bloomberg via Getty Images)
Merck's Keytruda blazes a path in first-line cervical cancer, making good on drugmaker's push for earlier patients
In the years since I/O wonder drug Keytruda’s initial approval, Merck has struck an aggressive clinical trial program, which is now firmly focused on earlier …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.